JP2023501155A5 - - Google Patents
Info
- Publication number
- JP2023501155A5 JP2023501155A5 JP2022524914A JP2022524914A JP2023501155A5 JP 2023501155 A5 JP2023501155 A5 JP 2023501155A5 JP 2022524914 A JP2022524914 A JP 2022524914A JP 2022524914 A JP2022524914 A JP 2022524914A JP 2023501155 A5 JP2023501155 A5 JP 2023501155A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- composition according
- concentration
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927720P | 2019-10-30 | 2019-10-30 | |
| US201962927716P | 2019-10-30 | 2019-10-30 | |
| US62/927,716 | 2019-10-30 | ||
| US62/927,720 | 2019-10-30 | ||
| US201962933692P | 2019-11-11 | 2019-11-11 | |
| US62/933,692 | 2019-11-11 | ||
| US201962936269P | 2019-11-15 | 2019-11-15 | |
| US62/936,269 | 2019-11-15 | ||
| PCT/US2020/057868 WO2021087050A1 (en) | 2019-10-30 | 2020-10-29 | Crizanlizumab containing antibody formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501155A JP2023501155A (ja) | 2023-01-18 |
| JP2023501155A5 true JP2023501155A5 (enExample) | 2023-11-07 |
Family
ID=73544317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524914A Pending JP2023501155A (ja) | 2019-10-30 | 2020-10-29 | クリザンリズマブ含有抗体製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220378912A1 (enExample) |
| EP (1) | EP4051236A1 (enExample) |
| JP (1) | JP2023501155A (enExample) |
| KR (1) | KR20220092917A (enExample) |
| CN (1) | CN114828826A (enExample) |
| AU (1) | AU2020373017B2 (enExample) |
| BR (1) | BR112022008097A2 (enExample) |
| CA (1) | CA3158921A1 (enExample) |
| CL (1) | CL2022001085A1 (enExample) |
| CO (1) | CO2022005207A2 (enExample) |
| EC (1) | ECSP22033601A (enExample) |
| IL (1) | IL292403A (enExample) |
| JO (1) | JOP20220097A1 (enExample) |
| MX (1) | MX2022005044A (enExample) |
| MY (1) | MY209141A (enExample) |
| PE (1) | PE20221276A1 (enExample) |
| PH (1) | PH12022551041A1 (enExample) |
| TW (1) | TWI893018B (enExample) |
| WO (1) | WO2021087050A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041957T2 (hu) | 2006-12-01 | 2019-06-28 | Novartis Ag | Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére |
| JOP20190101A1 (ar) * | 2016-11-03 | 2019-05-05 | Novartis Ag | أنظمة علاج |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CA3092931A1 (en) * | 2018-03-08 | 2019-09-12 | Novartis Ag | Use of an anti-p-selectin antibody |
-
2020
- 2020-10-29 TW TW109137726A patent/TWI893018B/zh active
- 2020-10-29 BR BR112022008097A patent/BR112022008097A2/pt unknown
- 2020-10-29 MY MYPI2022002262A patent/MY209141A/en unknown
- 2020-10-29 PH PH1/2022/551041A patent/PH12022551041A1/en unknown
- 2020-10-29 IL IL292403A patent/IL292403A/en unknown
- 2020-10-29 MX MX2022005044A patent/MX2022005044A/es unknown
- 2020-10-29 CA CA3158921A patent/CA3158921A1/en active Pending
- 2020-10-29 EP EP20811836.4A patent/EP4051236A1/en active Pending
- 2020-10-29 PE PE2022000689A patent/PE20221276A1/es unknown
- 2020-10-29 AU AU2020373017A patent/AU2020373017B2/en active Active
- 2020-10-29 US US17/771,353 patent/US20220378912A1/en active Pending
- 2020-10-29 WO PCT/US2020/057868 patent/WO2021087050A1/en not_active Ceased
- 2020-10-29 JP JP2022524914A patent/JP2023501155A/ja active Pending
- 2020-10-29 KR KR1020227017799A patent/KR20220092917A/ko active Pending
- 2020-10-29 CN CN202080075626.2A patent/CN114828826A/zh active Pending
-
2022
- 2022-04-26 CO CONC2022/0005207A patent/CO2022005207A2/es unknown
- 2022-04-27 JO JOP/2022/0097A patent/JOP20220097A1/ar unknown
- 2022-04-27 EC ECSENADI202233601A patent/ECSP22033601A/es unknown
- 2022-04-28 CL CL2022001085A patent/CL2022001085A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| JP2013511557A5 (enExample) | ||
| JP7229999B2 (ja) | ダプトマイシン製剤 | |
| JP2010511665A5 (enExample) | ||
| CN104010656A (zh) | 使用免疫球蛋白和c1-抑制剂的联合疗法 | |
| US20160143911A1 (en) | Stable and water soluble pharmaceutical compositions comprising pemetrexed | |
| JP2022539077A5 (enExample) | ||
| WO2023232095A9 (zh) | 一种基于病毒阻断剂的口腔喷雾制剂及其用途 | |
| JPH0380772B2 (enExample) | ||
| AU2020311050B2 (en) | Stable formulations of recombinant proteins | |
| JP2023501155A5 (enExample) | ||
| US20210228605A1 (en) | Isomorphs of remdesivir and methods for synthesis of same | |
| CN111386103B (zh) | 稳定的艾博韦泰组合物 | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| AU2021227095B2 (en) | Daptomycin formulation | |
| JP2024515555A5 (enExample) | ||
| JP2023524445A5 (enExample) | ||
| US12409139B2 (en) | Stable parenteral formulations of duloxetine | |
| CN108289840A (zh) | 用于静脉内注射Danirixin的制剂 | |
| KR20220163413A (ko) | 제약 제제 아드레노메둘린의 폴리에틸렌 글리콜계 전구약물 및 용도 | |
| JP2023510258A5 (enExample) |